Advertisement

Biodrug Suppresses Breast and Colorectal Cancer in Murine Models

  • Syed Sultan Beevi
  • Naveen Kumar Tangudu
  • Vinod Kumar Verma
  • Lekha Dinesh KumarEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1974)

Abstract

RNA interference (RNAi) remains one of the most promising and emerging strategies for the effective cancer treatment due to its high target specificity and greater potency. However, it is hindered due to lack of appropriate targeting technologies. Therefore, there is an imminent need to develop specific and robust delivery systems for successful gene silencing. Nanotechnology-based strategies have been in place to combat the shortcomings associated with viral-based delivery systems. Herein we describe protocols for successful in vitro and in vivo delivery of gene-specific nucleic acids such as siRNAs and shRNAs using PEI-PGMA nanoparticles for efficient cancer therapy.

Keywords

RNA interference Gene silencing Nanoparticles Cancer therapy 

Notes

Acknowledgments

We acknowledge all authors of original publication for their respective contribution to the original manuscript from where this protocol is derived.

References

  1. 1.
    Agrawal N, Dasaradhi PVN, Mohamed A, Malhotra P, Bhatnagar RK, Mukherjee SK (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67(4):657–685CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sledz CA, Williams BRG (2005) RNA interference in biology and disease. Blood 106(3):787–794CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rao M, Sockanathan S (2005) Molecular mechanisms of RNAi: implications for development and disease. Birth Defects Res C Embryo Today 75(1):28–42CrossRefPubMedGoogle Scholar
  4. 4.
    Caplen NJ (2004) Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther 11(16):1241–1248CrossRefPubMedGoogle Scholar
  5. 5.
    Ren YJ, Zhang Y (2014) An update on RNA interference-mediated gene silencing in cancer therapy. Expert Opin Biol Ther 14(11):1581–1592CrossRefPubMedGoogle Scholar
  6. 6.
    Phalon C, Rao DD, Nemunaitis J (2010) Potential use of RNA interference in cancer therapy. Expert Rev Mol Med 12:e26CrossRefPubMedGoogle Scholar
  7. 7.
    Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11(1):59–67CrossRefPubMedGoogle Scholar
  8. 8.
    Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4:346–358CrossRefPubMedGoogle Scholar
  9. 9.
    Höbel S, Aigner A (2010) Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo. Methods Mol Biol 623:283–297CrossRefPubMedGoogle Scholar
  10. 10.
    Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A (2005) A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. MolTher 11:990–995Google Scholar
  11. 11.
    Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Hobel S et al (2006) RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17:751–766CrossRefPubMedGoogle Scholar
  12. 12.
    Breunig M, Lungwitz U, Liebl R, Goepferich A (2007) Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci U S A 104:14454–14459CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Evans CW, Fitzgerald M, Clemons TD, House MJ, Padman BS, Shaw JA et al (2011) Multimodal analysis of PEI-mediated endocytosis of nanoparticles in neural Cells. ACS Nano 5:8640–8648CrossRefPubMedGoogle Scholar
  14. 14.
    Iyer KS, Zdyrko B, Malz H, Pionteck J, Luzinov I (2003) Polystyrene layers grafted to macromolecular anchoring layer. Macromolecules 36:6519–6526CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Syed Sultan Beevi
    • 1
    • 2
  • Naveen Kumar Tangudu
    • 1
    • 3
  • Vinod Kumar Verma
    • 1
    • 2
  • Lekha Dinesh Kumar
    • 1
    Email author
  1. 1.Cancer BiologyCSIR-Centre for Cellular and Molecular BiologyHyderabadIndia
  2. 2.Department of Cancer Biology, KIMS Foundation & Research CentreKIMS HospitalSecunderabadIndia
  3. 3.Institute of Comparative Molecular EndocrinologyUlm UniversityUlmGermany

Personalised recommendations